Heidelberg Pharma AG
XETRA:HPHA
Balance Sheet
Balance Sheet Decomposition
Heidelberg Pharma AG
Current Assets | 48.1m |
Cash & Short-Term Investments | 32.6m |
Receivables | 3.3m |
Other Current Assets | 12.2m |
Non-Current Assets | 13.6m |
PP&E | 3.7m |
Intangibles | 8.9m |
Other Non-Current Assets | 974.8k |
Current Liabilities | 16.5m |
Accounts Payable | 5.1m |
Short-Term Debt | 5.1m |
Other Current Liabilities | 6.3m |
Non-Current Liabilities | 69.8k |
Long-Term Debt | 69.8k |
Balance Sheet
Heidelberg Pharma AG
Nov-2015 | Nov-2016 | Nov-2017 | Nov-2018 | Nov-2019 | Nov-2020 | Nov-2021 | Nov-2022 | Nov-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash & Cash Equivalents |
1
|
5
|
30
|
19
|
10
|
5
|
6
|
81
|
43
|
|
Cash Equivalents |
1
|
5
|
30
|
19
|
10
|
5
|
6
|
81
|
43
|
|
Total Receivables |
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
2
|
|
Accounts Receivables |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
5
|
10
|
|
Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
|
Total Current Assets |
2
|
5
|
31
|
20
|
12
|
8
|
9
|
88
|
57
|
|
PP&E Net |
1
|
1
|
1
|
2
|
2
|
3
|
4
|
4
|
4
|
|
PP&E Gross |
1
|
1
|
1
|
2
|
2
|
3
|
4
|
4
|
4
|
|
Accumulated Depreciation |
3
|
3
|
3
|
4
|
4
|
5
|
6
|
6
|
7
|
|
Intangible Assets |
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
|
Goodwill |
6
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
|
Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Assets |
6
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
6
|
|
Total Assets |
12
N/A
|
15
+26%
|
41
+172%
|
31
-25%
|
23
-26%
|
20
-15%
|
22
+11%
|
101
+363%
|
70
-30%
|
|
Liabilities | ||||||||||
Accounts Payable |
0
|
0
|
2
|
0
|
1
|
3
|
1
|
3
|
8
|
|
Accrued Liabilities |
2
|
1
|
2
|
3
|
3
|
3
|
3
|
4
|
1
|
|
Short-Term Debt |
0
|
4
|
0
|
0
|
0
|
0
|
10
|
16
|
6
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Current Liabilities |
1
|
0
|
1
|
2
|
2
|
0
|
0
|
5
|
5
|
|
Total Current Liabilities |
3
|
5
|
4
|
5
|
6
|
7
|
15
|
28
|
20
|
|
Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
1
|
|
Total Liabilities |
3
N/A
|
5
+109%
|
4
-19%
|
5
+19%
|
7
+26%
|
7
+0%
|
15
+123%
|
34
+126%
|
21
-38%
|
|
Equity | ||||||||||
Common Stock |
9
|
13
|
22
|
28
|
28
|
31
|
34
|
47
|
47
|
|
Retained Earnings |
184
|
191
|
202
|
213
|
222
|
240
|
266
|
285
|
302
|
|
Additional Paid In Capital |
185
|
188
|
216
|
210
|
210
|
222
|
238
|
305
|
305
|
|
Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Equity |
9
N/A
|
10
+3%
|
37
+279%
|
26
-30%
|
16
-37%
|
13
-21%
|
7
-48%
|
67
+895%
|
49
-26%
|
|
Total Liabilities & Equity |
12
N/A
|
15
+26%
|
41
+172%
|
31
-25%
|
23
-26%
|
20
-15%
|
22
+11%
|
101
+363%
|
70
-30%
|
|
Shares Outstanding | ||||||||||
Common Shares Outstanding |
10
|
13
|
22
|
28
|
28
|
31
|
34
|
47
|
47
|